{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:04:42Z","timestamp":1791389082312,"version":"4.3.3"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40272-026-00763-4","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:47:39Z","timestamp":1787291259000},"page":"447-464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Model-Informed Precision Dosing in Pediatric Patients: Current Software Tools and Bedside Guided Application"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5972-7832","authenticated-orcid":false,"given":"Abdullah","family":"Aljutayli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emna","family":"Gaies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S.","family":"Alasmari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekra Kamel","family":"Aljehani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrar","family":"Samman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Abudahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Abouelkheir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alsultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"Suppl. 1","key":"763_CR1","first-page":"S125","volume":"61","author":"P Jarugula","year":"2021","unstructured":"Jarugula P, Scott S, Ivaturi V, Noack A, Moffett BS, Bhutta A, et al. Understanding the role of pharmacometrics-based clinical decision support systems in pediatric patient management: a case study using Lyv software. J Clin Pharmacol. 2021;61(Suppl. 1):S125\u201332.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"763_CR2","first-page":"695","volume":"103","author":"CIS Barker","year":"2018","unstructured":"Barker CIS, Standing JF, Kelly LE, Hanly Faught L, Needham AC, Rieder MJ, et al. Pharmacokinetic studies in children: recommendations for practice and research. Arch Dis Child. 2018;103(7):695\u2013702.","journal-title":"Arch Dis Child"},{"key":"763_CR3","unstructured":"EMA. 10\u2010Year report to the European Commission: general report on the experience acquired as a result of the application of the Paediatric Regulation. 2016. https:\/\/health.ec.europa.eu\/system\/files\/2020-06\/paediatrics_10_years_ema_technical_report_0.pdf. Accessed 16 Jul 2026."},{"issue":"11","key":"763_CR4","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1080\/17512433.2021.1961578","volume":"14","author":"Q Tu","year":"2021","unstructured":"Tu Q, Cotta M, Raman S, Graham N, Schlapbach L, Roberts JA. Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations. Expert Rev Clin Pharmacol. 2021;14(11):1383\u201399.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"763_CR5","first-page":"262","volume":"19","author":"H Lu","year":"2014","unstructured":"Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19(4):262\u201376.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"Suppl. 10","key":"763_CR6","first-page":"S108","volume":"58","author":"J Le","year":"2018","unstructured":"Le J, Bradley JS. Optimizing antibiotic drug therapy in pediatrics: current state and future needs. J Clin Pharmacol. 2018;58(Suppl. 10):S108\u201322.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"763_CR7","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1128\/IAI.74.4.1999-2006.2006","volume":"74","author":"L Mar\u00f3di","year":"2006","unstructured":"Mar\u00f3di L. Neonatal innate immunity to infectious agents. Infect Immun. 2006;74(4):1999\u20132006.","journal-title":"Infect Immun"},{"issue":"3","key":"763_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.5863\/1551-6776-25.3.175","volume":"25","author":"RS Meyers","year":"2020","unstructured":"Meyers RS, Thackray J, Matson KL, McPherson C, Lubsch L, Hellinga RC, et al. Key potentially inappropriate drugs in pediatrics: the KIDs list. J Pediatr Pharmacol Ther. 2020;25(3):175\u201391. https:\/\/doi.org\/10.5863\/1551-6776-25.3.175.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"763_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00431-019-03556-9","volume":"179","author":"L Schrier","year":"2020","unstructured":"Schrier L, Hadjipanayis A, Stiris T, Ross-Russell RI, Valiulis A, Turner MA, et al. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European Society for Developmental Perinatal and Pediatric Pharmacology. Eur J Pediatr. 2020;179(5):839\u201347.","journal-title":"Eur J Pediatr"},{"issue":"2","key":"763_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/cts.12607","volume":"12","author":"MJ McLaughlin","year":"2019","unstructured":"McLaughlin MJ, Wagner J, Shakhnovich V, Carleton B, Leeder JS. Considerations for implementing precision therapeutics for children. Clin Transl Sci. 2019;12(2):140\u201350.","journal-title":"Clin Transl Sci"},{"issue":"8","key":"763_CR11","first-page":"776","volume":"111","author":"HC Allen","year":"2018","unstructured":"Allen HC, Garbe MC, Lees J, Aziz N, Chaaban H, Miller JL, et al. Off-label medication use in children, more common than we think: a systematic review of the literature. J Okla State Med Assoc. 2018;111(8):776\u201383.","journal-title":"J Okla State Med Assoc"},{"issue":"9","key":"763_CR12","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1007\/s00431-022-04515-7","volume":"181","author":"M Meng","year":"2022","unstructured":"Meng M, Lv M, Wang L, Yang B, Jiao P, Lei W, et al. Off-label use of drugs in pediatrics: a scoping review. Eur J Pediatr. 2022;181(9):3259\u201369.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"763_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1026","volume":"10","author":"A Chen","year":"2022","unstructured":"Chen A, Gupta A, Do DH, Nazer LH. Bayesian method application: Integrating mathematical modeling into clinical pharmacy through vancomycin therapeutic monitoring. Pharmacol Res Perspect. 2022;10(6):e01026.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"763_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s40272-024-00633-x","volume":"26","author":"K Meesters","year":"2024","unstructured":"Meesters K, Balbas-Martinez V, Allegaert K, Downes KJ, Michelet R. Personalized dosing of medicines for children: a primer on pediatric pharmacometrics for clinicians. Paediatr Drugs. 2024;26(4):365\u201379.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"763_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","volume":"42","author":"GG Rao","year":"2020","unstructured":"Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2020;42(1):83\u201392.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"763_CR16","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/bcp.14066","volume":"85","author":"AA Kumar","year":"2019","unstructured":"Kumar AA, Burgard M, Stacey S, Sandaradura I, Lai T, Coorey C, et al. An evaluation of the user-friendliness of Bayesian forecasting programs in a clinical setting. Br J Clin Pharmacol. 2019;85(10):2436\u201341.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"763_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/imj.13412","volume":"47","author":"J Donagher","year":"2017","unstructured":"Donagher J, Martin JH, Barras MA. Individualised medicine: why we need Bayesian dosing. Intern Med J. 2017;47(5):593\u2013600.","journal-title":"Intern Med J"},{"issue":"5","key":"763_CR18","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/cpt.659","volume":"101","author":"AS Darwich","year":"2017","unstructured":"Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017;101(5):646\u201356.","journal-title":"Clin Pharmacol Ther"},{"key":"763_CR19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fphar.2020.00620","volume":"11","author":"W Kantasiripitak","year":"2020","unstructured":"Kantasiripitak W, Van Daele R, Gijsen M, Ferrante M, Spriet I, Dreesen E. Software tools for model-informed precision dosing: how well do they satisfy the needs? Front Pharmacol. 2020;11:620.","journal-title":"Front Pharmacol"},{"issue":"4","key":"763_CR20","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/bcp.15978","volume":"90","author":"N Holford","year":"2024","unstructured":"Holford N, O\u2019Hanlon CJ, Allegaert K, Anderson B, Falc\u00e3o A, Simon N, et al. A physiological approach to renal clearance: from premature neonates to adults. Br J Clin Pharmacol. 2024;90(4):1066\u201380.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"763_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/pan.12176","volume":"24","author":"K Allegaert","year":"2014","unstructured":"Allegaert K, van de Velde M, van den Anker J. Neonatal clinical pharmacology. Paediatr Anaesth. 2014;24(1):30\u20138.","journal-title":"Paediatr Anaesth"},{"issue":"9","key":"763_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1136\/archdischild-2013-303720","volume":"98","author":"BJ Anderson","year":"2013","unstructured":"Anderson BJ, Holford NH. Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child. 2013;98(9):737\u201344.","journal-title":"Arch Dis Child"},{"issue":"3","key":"763_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1460-9592.2011.03523.x","volume":"21","author":"E Manolis","year":"2011","unstructured":"Manolis E, Osman TE, Herold R, Koenig F, Tomasi P, Vamvakas S, et al. Role of modeling and simulation in pediatric investigation plans. Paediatr Anaesth. 2011;21(3):214\u201321.","journal-title":"Paediatr Anaesth"},{"issue":"1","key":"763_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24(1):25\u201336.","journal-title":"Drug Metab Pharmacokinet"},{"key":"763_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107541","volume":"211","author":"LFM Verscheijden","year":"2020","unstructured":"Verscheijden LFM, Koenderink JB, Johnson TN, de Wildt SN, Russel FGM. Physiologically-based pharmacokinetic models for children: starting to reach maturation? Pharmacol Ther. 2020;211:107541.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"763_CR26","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.pedneo.2022.10.006","volume":"64","author":"M Abouelkheir","year":"2023","unstructured":"Abouelkheir M, Almohaizeie A, Almutairi A, Almuhisen S, Alqahtani S, Alsultan A. Evaluation of vancomycin individualized model-based dosing approach in neonates. Pediatr Neonatol. 2023;64(3):327\u201334.","journal-title":"Pediatr Neonatol"},{"issue":"2","key":"763_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/jpids\/pix109","volume":"8","author":"A Frymoyer","year":"2019","unstructured":"Frymoyer A, Stockmann C, Hersh AL, Goswami S, Keizer RJ. Individualized empiric vancomycin dosing in neonates using a model-based approach. J Pediatr Infect Dis Soc. 2019;8(2):97\u2013104.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"763_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00888","volume":"11","author":"P Shukla","year":"2020","unstructured":"Shukla P, Goswami S, Keizer RJ, Winger BA, Kharbanda S, Dvorak CC, et al. Assessment of a model-informed precision dosing platform use in routine clinical care for personalized busulfan therapy in the pediatric hematopoietic cell transplantation (HCT) population. Front Pharmacol. 2020;11:888.","journal-title":"Front Pharmacol"},{"issue":"3","key":"763_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10928-024-09915-w","volume":"51","author":"JH Hughes","year":"2024","unstructured":"Hughes JH, Long-Boyle J, Keizer RJ. Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing. J Pharmacokinet Pharmacodyn. 2024;51(3):279\u201388.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"763_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77(11):835\u201364.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"763_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/FTD.0000000000001250","volume":"47","author":"S Masuda","year":"2025","unstructured":"Masuda S, Lemaitre F, Barten MJ, Bergan S, Shipkova M, van Gelder T, et al. Everolimus personalized therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2025;47(1):4\u201331.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"763_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"763_CR33","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361\u20134.","journal-title":"Clin Infect Dis"},{"key":"763_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3389\/fphar.2020.00420","volume":"11","author":"RJ Tyson","year":"2020","unstructured":"Tyson RJ, Park CC, Powell JR, Patterson JH, Weiner D, Watkins PB, et al. Precision dosing priority criteria: drug, disease, and patient population variables. Front Pharmacol. 2020;11:420.","journal-title":"Front Pharmacol"},{"issue":"6","key":"763_CR35","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/cts.12490","volume":"10","author":"D Gonzalez","year":"2017","unstructured":"Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, et al. Precision dosing: public health need, proposed framework, and anticipated impact. Clin Transl Sci. 2017;10(6):443\u201354.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"763_CR36","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/cpdd.638","volume":"8","author":"TM Polasek","year":"2019","unstructured":"Polasek TM, Rayner CR, Peck RW, Rowland A, Kimko H, Rostami-Hodjegan A. Toward dynamic prescribing information: codevelopment of companion model-informed precision dosing tools in drug development. Clin Pharmacol Drug Dev. 2019;8(4):418\u201325.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"763_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.624639","volume":"9","author":"A Abdulla","year":"2021","unstructured":"Abdulla A, Edwina AE, Flint RB, Allegaert K, Wildschut ED, Koch BCP, et al. Model-informed precision dosing of antibiotics in pediatric patients: a narrative review. Front Pediatr. 2021;9:624639.","journal-title":"Front Pediatr"},{"issue":"6","key":"763_CR38","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0010-4809(69)90030-5","volume":"2","author":"LB Sheiner","year":"1969","unstructured":"Sheiner LB. Computer-aided long-term anticoagulation therapy. Comput Biomed Res. 1969;2(6):507\u201318.","journal-title":"Comput Biomed Res"},{"issue":"3","key":"763_CR39","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/00007691-200006000-00018","volume":"22","author":"R Jelliffe","year":"2000","unstructured":"Jelliffe R, Bayard D, Milman M, Van Guilder M, Schumitzky A. Achieving target goals most precisely using nonparametric compartmental models and \u201cmultiple model\u201d design of dosage regimens. Ther Drug Monit. 2000;22(3):346\u201353.","journal-title":"Ther Drug Monit"},{"key":"763_CR40","unstructured":"Jelliffe RW. The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic\/dynamic systems, and adaptive control of drug dosage regimens. Proc Annu Symp Comput Appl Med Care. 1991;922\u20134."},{"issue":"6","key":"763_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/BF01060053","volume":"8","author":"LB Sheiner","year":"1980","unstructured":"Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8(6):553\u201371.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"763_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0010-4809(72)90051-1","volume":"5","author":"LB Sheiner","year":"1972","unstructured":"Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):411\u201359.","journal-title":"Comput Biomed Res"},{"key":"763_CR43","doi-asserted-by":"crossref","unstructured":"Kisor DF, Watling SM, Zarowitz BJ, Jelliffe RW. Population pharmacokinetics of gentamicin. Use of the nonparametric expectation maximisation (NPEM) algorithm. Clin Pharmacokinet. 1992;23(1):62\u20138.","DOI":"10.2165\/00003088-199223010-00005"},{"issue":"12","key":"763_CR44","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/psp4.12353","volume":"7","author":"RJ Keizer","year":"2018","unstructured":"Keizer RJ, Ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S. Model-informed precision dosing at the bedside: scientific challenges and opportunities. CPT Pharmacomet Syst Pharmacol. 2018;7(12):785\u20137.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"763_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","volume":"61","author":"AS Darwich","year":"2021","unstructured":"Darwich AS, Polasek TM, Aronson JK, Ogungbenro K, Wright DFB, Achour B, et al. Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy. Annu Rev Pharmacol Toxicol. 2021;61:225\u201345.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"763_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/9781118784860","volume-title":"Introduction to population pharmacokinetic\/pharmacodynamic analysis with nonlinear mixed effects models","author":"JS Owen","year":"2014","unstructured":"Owen JS, Fiedler-Kelly J. Introduction to population pharmacokinetic\/pharmacodynamic analysis with nonlinear mixed effects models. Hoboken, NJ:  Wiley; 2014."},{"issue":"9","key":"763_CR47","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1007\/s00431-023-05103-z","volume":"182","author":"R Velarde-Salcedo","year":"2023","unstructured":"Velarde-Salcedo R, P\u00e9rez-Gonz\u00e1lez LF, Rodr\u00edguez-B\u00e1ez AS, Arriaga-Garc\u00eda FJ, Mil\u00e1n-Segovia RDC, Romano-Moreno S, et al. Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program. Eur J Pediatr. 2023;182(9):4143\u201352.","journal-title":"Eur J Pediatr"},{"key":"763_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071859","author":"P Del Valle-Moreno","year":"2023","unstructured":"Del Valle-Moreno P, Suarez-Casillas P, Mej\u00edas-Trueba M, Ciudad-Guti\u00e9rrez P, Guisado-Gil AB, Gil-Navarro MV, et al. Model-informed precision dosing software tools for dosage regimen individualization: a scoping review. Pharmaceutics. 2023;15(7):1859. https:\/\/doi.org\/10.3390\/pharmaceutics15071859.","journal-title":"Pharmaceutics"},{"issue":"3","key":"763_CR49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40262-024-01353-8","volume":"63","author":"D Alrahahleh","year":"2024","unstructured":"Alrahahleh D, Thoma Y, Van Daele R, Nguyen T, Halena S, Luig M, et al. Bayesian vancomycin model selection for therapeutic drug monitoring in neonates. Clin Pharmacokinet. 2024;63(3):367\u201380.","journal-title":"Clin Pharmacokinet"},{"key":"763_CR50","doi-asserted-by":"publisher","unstructured":"De Cock RFW, Allegaert K, Sherwin CMT, Nielsen EI, de Hoog M, van den Anker JN, et al. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res. 2014;31(3):754\u201367.\u00a0https:\/\/doi.org\/10.1007\/s11095-013-1197-y.","DOI":"10.1007\/s11095-013-1197-y"},{"issue":"2","key":"763_CR51","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02046-21","volume":"66","author":"MH Alshaer","year":"2022","unstructured":"Alshaer MH, Goutelle S, Santevecchi BA, Shoulders BR, Venugopalan V, Cherabuddi K, et al. Cefepime precision dosing tool: from standard to precise dose using nonparametric population pharmacokinetics. Antimicrob Agents Chemother. 2022;66(2):e0204621.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"763_CR52","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s00228-024-03762-x","volume":"80","author":"A Alsultan","year":"2024","unstructured":"Alsultan A, Almofada R, Alomair S, Egelund EF, Albassam AA, Ali M, et al. Evaluation of the predictive performance of an online voriconazole dose calculator in children. Eur J Clin Pharmacol. 2024;80(12):1989\u201393.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"763_CR53","first-page":"603","volume":"28","author":"Y Avalos","year":"2023","unstructured":"Avalos Y, Gothard MD, Moses J, Finkler M. Retrospective assessment of an adalimumab model-informed precision dosing support tool for use in pediatric inflammatory bowel disease. J Pediatr Pharmacol Ther. 2023;28(7):603\u20139.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"763_CR54","doi-asserted-by":"publisher","unstructured":"de Klaver PAG, Keizer RJ, ter Heine R, Smits L, Boekema PJ, Kuntzel I, et al. Early at-home measurement of adalimumab concentrations to guide anti-TNF precision dosing: a pilot study. Eur J Drug Metab Pharmacokinet. 2023;48(4):377\u201385.\u00a0https:\/\/doi.org\/10.1007\/s13318-023-00835-7.","DOI":"10.1007\/s13318-023-00835-7"},{"key":"763_CR55","doi-asserted-by":"publisher","unstructured":"Ternant D, Karmiris K, Vermeire S, Desvignes C, Azzopardi N, Bejan-Angoulvant T, et al. Pharmacokinetics of adalimumab in Crohn\u2019s disease. Eur J Clin Pharmacol. 2015;71(9):1155\u20137.\u00a0https:\/\/doi.org\/10.1007\/s00228-015-1892-1.","DOI":"10.1007\/s00228-015-1892-1"},{"issue":"6","key":"763_CR56","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/FTD.0000000000001217","volume":"46","author":"K Ben Hassine","year":"2024","unstructured":"Ben Hassine K, Daali Y, Gloor Y, Nava T, Th\u00e9or\u00eat Y, Krajinovic M, et al. Simulation-based optimization of sampling schedules for model-informed precision dosing of once-daily and 4-times-daily busulfan in pediatric patients. Ther Drug Monit. 2024;46(6):786\u201396.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"763_CR57","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s40262-017-0610-9","volume":"57","author":"M Burgard","year":"2018","unstructured":"Burgard M, Sandaradura I, van Hal SJ, Stacey S, Hennig S. Evaluation of tobramycin exposure predictions in three Bayesian forecasting programmes compared with current clinical practice in children and adults with cystic fibrosis. Clin Pharmacokinet. 2018;57(8):1017\u201327.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"763_CR58","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00134-024-07353-3","volume":"50","author":"MG Chai","year":"2024","unstructured":"Chai MG, Tu Q, Cotta MO, Bauer MJ, Balch R, Okafor C, et al. Achievement of therapeutic antibiotic exposures using Bayesian dosing software in critically unwell children and adults with sepsis. Intensive Care Med. 2024;50(4):539\u201347.","journal-title":"Intensive Care Med"},{"issue":"1","key":"763_CR59","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00228-020-02975-0","volume":"77","author":"MB Dave","year":"2021","unstructured":"Dave MB, Dherai AJ, Desai DC, Mould DR, Ashavaid TF. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience. Eur J Clin Pharmacol. 2021;77(1):55\u201362.","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"763_CR60","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/ibd\/izab285","volume":"28","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Mendiolaza ML, Phan BL, Moran HR, Tse SS, Mould DR. Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity. Inflamm Bowel Dis. 2022;28(9):1375\u201385.","journal-title":"Inflamm Bowel Dis"},{"key":"763_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102408","author":"MC Dubinsky","year":"2023","unstructured":"Dubinsky MC, Rabizadeh S, Panetta JC, Spencer EA, Everts-van der Wind A, Dervieux T. The combination of predictive factors of pharmacokinetic origin associates with enhanced disease control during treatment of pediatric Crohn\u2019s disease with infliximab. Pharmaceutics. 2023;15(10):2408.\u00a0https:\/\/doi.org\/10.3390\/pharmaceutics15102408.","journal-title":"Pharmaceutics"},{"key":"763_CR62","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3389\/fphar.2020.00551","volume":"11","author":"A Frymoyer","year":"2020","unstructured":"Frymoyer A, Schwenk HT, Zorn Y, Bio L, Moss JD, Chasmawala B, et al. Model-informed precision dosing of vancomycin in hospitalized children: implementation and adoption at an academic children\u2019s hospital. Front Pharmacol. 2020;11:551.","journal-title":"Front Pharmacol"},{"issue":"10","key":"763_CR63","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/phar.2845","volume":"43","author":"A Frymoyer","year":"2023","unstructured":"Frymoyer A, Schwenk HT, Brockmeyer JM, Bio L. Impact of model-informed precision dosing on achievement of vancomycin exposure targets in pediatric patients with cystic fibrosis. Pharmacotherapy. 2023;43(10):1007\u201314.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"763_CR64","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1128\/AAC.00577-16","volume":"60","author":"E Germovsek","year":"2016","unstructured":"Germovsek E, Kent A, Metsvaht T, Lutsar I, Klein N, Turner MA, et al. Development and evaluation of a gentamicin pharmacokinetic model that facilitates opportunistic gentamicin therapeutic drug monitoring in neonates and infants. Antimicrob Agents Chemother. 2016;60(8):4869\u201377.","journal-title":"Antimicrob Agents Chemother"},{"key":"763_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102107","author":"S Goutelle","year":"2022","unstructured":"Goutelle S, Thoma Y, Buffet R, Philippe M, Buclin T, Guidi M, et al. Implementation and cross-validation of a pharmacokinetic model for precision dosing of busulfan in hematopoietic stem cell transplanted children. Pharmaceutics. 2022;14(10):2107.\u00a0https:\/\/doi.org\/10.3390\/pharmaceutics14102107.","journal-title":"Pharmaceutics"},{"key":"763_CR66","doi-asserted-by":"publisher","unstructured":"Paci A, Vassal G, Moshous D, Dalle J-H, Bleyzac N, Neven B, et al. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther Drug Monit. 2012;34(2):198\u2013208.\u00a0https:\/\/doi.org\/10.1097\/FTD.0b013e31824c2f60.","DOI":"10.1097\/FTD.0b013e31824c2f60"},{"issue":"4","key":"763_CR67","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-014-0211-9","volume":"54","author":"S Hennig","year":"2015","unstructured":"Hennig S, Holthouse F, Staatz CE. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis. Clin Pharmacokinet. 2015;54(4):409\u201321.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"763_CR68","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/FTD.0000000000001161","volume":"46","author":"RA Hermans","year":"2024","unstructured":"Hermans RA, Storm AEM, Kloosterboer SM, Hillegers MHJ, Koch BCP, Dierckx B, et al. Therapeutic drug monitoring to optimize risperidone treatment in children with autism spectrum disorder. Ther Drug Monit. 2024;46(2):259\u201364.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"763_CR69","first-page":"434","volume":"75","author":"DM Hughes","year":"2020","unstructured":"Hughes DM, Goswami S, Keizer RJ, Hughes MA, Faldasz JD. Bayesian clinical decision support-guided versus clinician-guided vancomycin dosing in attainment of targeted pharmacokinetic parameters in a paediatric population. J Antimicrob Chemother. 2020;75(2):434\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"763_CR70","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1093\/jac\/dkac324","volume":"77","author":"S Imani","year":"2022","unstructured":"Imani S, Fitzgerald DA, Robinson PD, Selvadurai H, Sandaradura I, Lai T. Personalized tobramycin dosing in children with cystic fibrosis: a comparative clinical evaluation of log-linear and Bayesian methods. J Antimicrob Chemother. 2022;77(12):3358\u201366.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"763_CR71","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/ecco-jcc\/jjad009","volume":"17","author":"W Kantasiripitak","year":"2023","unstructured":"Kantasiripitak W, Wicha SG, Thomas D, Hoffman I, Ferrante M, Vermeire S, et al. A model-based tool for guiding infliximab induction dosing to maximize long-term deep remission in children with inflammatory bowel diseases. J Crohns Colitis. 2023;17(6):896\u2013908.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"763_CR72","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s13318-024-00920-5","volume":"49","author":"T Laitila","year":"2024","unstructured":"Laitila T, Sankilampi U, Renko M, Kokki M, Ranta VP. Comparison of vancomycin AUC24 calculation methods for neonates and infants. Eur J Drug Metab Pharmacokinet. 2024;49(6):773\u20139.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"763_CR73","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00280-021-04288-0","volume":"88","author":"R Lawson","year":"2021","unstructured":"Lawson R, Paterson L, Fraser CJ, Hennig S. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation. Cancer Chemother Pharmacol. 2021;88(3):379\u201391.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"763_CR74","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/FTD.0000000000000276","volume":"38","author":"M Neely","year":"2016","unstructured":"Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D, et al. Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software. Ther Drug Monit. 2016;38(3):332\u201342.","journal-title":"Ther Drug Monit"},{"key":"763_CR75","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00707-17","author":"V Ramos-Mart\u00edn","year":"2017","unstructured":"Ramos-Mart\u00edn V, Neely MN, Padmore K, Peak M, Beresford MW, Turner MA, et al. Tools for the individualized therapy of teicoplanin for neonates and children. Antimicrob Agents Chemother. 2017;61(10):e00707\u201317. https:\/\/doi.org\/10.1128\/AAC.00707-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"763_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14102089","author":"DMH Tong","year":"2022","unstructured":"Tong DMH, Hughes JH, Keizer RJ. Evaluating and improving neonatal gentamicin pharmacokinetic models using aggregated routine clinical care data. Pharmaceutics. 2022;14(10):2089.\u00a0https:\/\/doi.org\/10.3390\/pharmaceutics14102089.","journal-title":"Pharmaceutics"},{"issue":"9","key":"763_CR77","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","volume":"23","author":"K Brendel","year":"2006","unstructured":"Brendel K, Comets E, Laffont C, Laveille C, Mentr\u00e9 F. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036\u201349.","journal-title":"Pharm Res"},{"key":"763_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115421","volume":"215","author":"IK Minichmayr","year":"2024","unstructured":"Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, et al. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024;215:115421.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"763_CR79","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503\u201312.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"763_CR80","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"4","key":"763_CR81","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40262-023-01233-7","volume":"62","author":"M El Hassani","year":"2023","unstructured":"El Hassani M, Marsot A. External evaluation of population pharmacokinetic models for precision dosing: current state and knowledge gaps. Clin Pharmacokinet. 2023;62(4):533\u201340.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"763_CR82","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/jac5.1017","volume":"1","author":"NF Pearce","year":"2018","unstructured":"Pearce NF, Giblin EM, Buckthal C, Ferrari A, Powell JR, Cao Y, et al. Precision drug dosing: a major opportunity for patients and pharmacists. J Am Coll Clin Pharm. 2018;1(1):107\u201312.","journal-title":"J Am Coll Clin Pharm."},{"issue":"12","key":"763_CR83","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1002\/psp4.13056","volume":"12","author":"ZL Taylor","year":"2023","unstructured":"Taylor ZL, Poweleit EA, Paice K, Somers KM, Pavia K, Vinks AA, et al. Tutorial on model selection and validation of model input into precision dosing software for model-informed precision dosing. CPT Pharmacomet Syst Pharmacol. 2023;12(12):1827\u201345.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"2","key":"763_CR84","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00228-024-03780-9","volume":"81","author":"A Alsultan","year":"2025","unstructured":"Alsultan A, Aljutayli A, Aljouie A, Albassam A, Woillard JB. Leveraging machine learning in limited sampling strategies for efficient estimation of the area under the curve in pharmacokinetic analysis: a review. Eur J Clin Pharmacol. 2025;81(2):183\u2013201.","journal-title":"Eur J Clin Pharmacol"},{"key":"763_CR85","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00860-24","author":"L Ponthier","year":"2024","unstructured":"Ponthier L, Franck B, Autmizguine J, Labriffe M, Ovetchkine P, Marquet P, et al. Application of machine-learning models to predict the ganciclovir and valganciclovir exposure in children using a limited sampling strategy. Antimicrob Agents Chemother. 2024. https:\/\/doi.org\/10.1128\/aac.00860-24.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"763_CR86","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40262-023-01310-x","volume":"62","author":"K Stankevi\u010di\u016bt\u0117","year":"2023","unstructured":"Stankevi\u010di\u016bt\u0117 K, Woillard JB, Peck RW, Marquet P, van der Schaar M. Bridging the worlds of pharmacometrics and machine learning. Clin Pharmacokinet. 2023;62(11):1551\u201365.","journal-title":"Clin Pharmacokinet"},{"key":"763_CR87","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081530","author":"L Keutzer","year":"2022","unstructured":"Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, et al. Machine learning and pharmacometrics for prediction of pharmacokinetic data: differences, similarities and challenges illustrated with rifampicin. Pharmaceutics. 2022;14(8):1530. https:\/\/doi.org\/10.3390\/pharmaceutics14081530.","journal-title":"Pharmaceutics"},{"key":"763_CR88","volume":"15","author":"K Sridharan","year":"2024","unstructured":"Sridharan K, Sivaramakrishnan G. Unlocking the potential of advanced large language models in medication review and reconciliation: a proof-of-concept investigation. Explor Res Clin Soc Pharm. 2024;15:100492.","journal-title":"Explor Res Clin Soc Pharm."},{"key":"763_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00177","volume":"11","author":"T Buclin","year":"2020","unstructured":"Buclin T, Thoma Y, Widmer N, Andr\u00e9 P, Guidi M, Csajka C, et al. The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib. Front Pharmacol. 2020;11:177.","journal-title":"Front Pharmacol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00763-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00763-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00763-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:08:09Z","timestamp":1790683689000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00763-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00763-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Abdullah Aljutayli, Emna Gaies, Mohammed S. Alasmari, Zekra Kamel Aljehani, Abrar Samman, Sara Abudahab, Manal Abouelkheir, and Abdullah Alsultan have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data generated or analyzed during this study are included in this published article and its supplementary information files.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AAJ, AAS, MAB, and ZA contributed to the study concept. AAJ and AAS contributed to the methodology. AAJ, AS, EG, SA, and MSA prepared the tables and summarized the included studies. AAJ, AAS, MAA, MAB, and ZA wrote sections of the manuscript. All authors reviewed and approved the final manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}